We believe making our medicines cost-efficient for both doctors and patients will give us a strong, lasting brand identity.
Brooksville, FL (PRWEB) April 18, 2012
In a bold strategic move, pharmaceuticals distributor MCR American Pharmaceuticals will cut out the pharmacy middleman and sell its medications directly to doctors, Chief Executive Officer David Daniel Ambrose announced today.
MCR American Pharmaceuticals’ new direct-purchase system, which launched this week, will allow doctors to distribute medicine directly to patients in their offices, David Daniel Ambrose said, saving both time and money. In addition to sparing the patient an extra trip to the pharmacy, this will give doctors more direct control over the treatment process – and ensure MCR American Pharmaceuticals’ products are administered.
“Doctors will be able to make sure the patient gets the medication they want, as opposed to the medication substituted by the pharmacy,” David Daniel Ambrose said. “When you go to a pharmacy, you might get a generic version of a similar medicine. This way, we’re ensured the patient gets our top-of-the-line product.”
In MCR American Pharmaceuticals’ case, that means more patients will be taking brand-name medications including the 20-product family of Maxiphen and Maxifed expectorants/decongestants, which are among the products currently available through the direct-purchase system. David Daniel Ambrose said more medications would before available by the end of April.
“We’re working hard to include more products in our slate of direct-purchase options,” noted MCR American Pharmaceuticals employee Daniel Dean. “David Daniel Ambrose recognizes that product availability is the key to this new distribution strategy, especially regarding availability on our new website.”
The chief executive, who took over MCR American Pharmaceuticals in 1999 after starting in its sales department just two years prior, said the direct-purchase system – which has been under development for about a year – is unique in the pharmaceuticals trade. But the idea will gain steam quickly, according to David Daniel Ambrose, who expects other pharmaceuticals distributors to catch on quick.
The idea, David Daniel Ambrose added, is to get out in front early.
“By being the first to attempt this distribution strategy, we believe we’ll be the best,” David Daniel Ambrose said. “We have every faith in our excellent product line, and we believe making our medicines cost-efficient for both doctors and patients will give us a strong, lasting brand identity.”
The new strategy is bolstered by the launch of MCR American Pharmaceuticals’ new website at mcramerican.com, which includes a thorough catalog of MCR American Pharmaceutical’s products, an ordering page and an interactive feature allowing doctors to submit questions or request further information about the company and its products.
About five doctors have signed on to the new system so far, but David Daniel Ambrose said he hopes to quadruple that number by next month.
“We wanted to start slow with a few key doctors that we already had some connections with and work the kinks out of the process,” David Daniel Ambrose said. “It’s a highly competitive marketplace and the industry is always changing. You need to be able to help the doctors fill the needs of the patients in the best way possible.”
About David Daniel Ambrose
David Daniel Ambrose is a pharmaceutical company chief executive with more than 15 years of industry experience. David Ambrose is the CEO of MCR American Pharmaceuticals and TG United Inc, as well as parent company Neural High-Tech Pharmaceuticals, all based on Brooksville, Florida. David Daniel Ambrose received a bachelor’s degree in finance from West Virginia University in 1990 and lives in Brooksville with his wife of 18 years, Amanda, and their three children.